[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100405332":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":55,"collaborators":18,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":18,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":18,"enrollmentInfo":66,"targetDuration":18,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":18,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Third Military Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Erythrocytapheresis","EXPERIMENTAL","Erythrocytapheresis plus standard of care",[13],"Procedure: Erythropheresis",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of care","NO_INTERVENTION","Oxygen delivery and basic care",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","Erythropheresis","The procedure involves the extracorporeal removal of a specific volume of erythrocytes using an automated cell separator. Following the centrifugal separation of whole blood, the patient's plasma and other cellular components are concurrently re-infused, often supplemented with a replacement fluid (such as saline) to maintain isovolemia.",[9],[26],{"name":27,"affiliation":5,"role":28},"Ye Fan","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Jieru Guo","CONTACT","+8618883923067","1193341071@qq.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"NO.953 Hospital","RECRUITING","Xigazê","Tibet","857000","China","CN",{"type":45,"coordinates":46},"Point",[47,48],88.88333,29.25,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":18,"email":54},"Jun Liang","18189028559","906585334@qq.com",{"type":28,"investigatorFullName":27,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Principal Investigator","100405332","erythrocytapheresis-for-chronic-mountain-sickness-100405332",false,"NCT04557995","Erythrocytapheresis for Chronic Mountain Sickness","Efficacy and Safety of Erythrocytapheresis in Chronic Mountain Sickness: the ESCAPE-CMS Trial","Inclusion:\n\n1. Age ≥18 years;\n2. High-altitude residents or long-term dwellers (continuous residence at ≥2500 meters above sea level for at least 1 year), with no travel history to low-altitude areas in the past 3 months;\n3. Hemoglobin (Hb): Men: ≥210 g\u002FL, Women: ≥190 g\u002FL; at least one symptom or sign: headache, dizziness, dyspnea, palpitations, sleep disturbances, fatigue, localized cyanosis, burning sensation in palms\u002Fsoles, venous dilatation, muscle\u002Fjoint pain, loss of appetite, poor concentration, or memory changes; CMS total score ≥6;\n4. Written informed consent obtained from patients or their legal representatives.\n\nExclusion:\n\n1. Hematocrit \\\u003C 60%;\n2. Patients with erythrocytosis attributable to: polycythemia vera; secondary erythrocytosis due to dehydration, cyanotic congenital heart disease, or chronic obstructive pulmonary disease; or other underlying hematologic or oncologic conditions;\n3. Patients with active pneumonia, pulmonary embolism, or severe organ dysfunction (including cardiac, hepatic, or renal failure);\n4. Patients with contraindications to study procedures (including erythrocytapheresis, pulmonary function tests, or incremental shuttle walk test), such as impaired consciousness, pneumothorax, severe arrhythmia, or significant coagulation disorders;\n5. Patients who have received CMS-specific interventions within the last 6 months, including phlebotomy, erythrocytapheresis, or targeted pharmacotherapy;\n6. Patients currently pregnant, breastfeeding, or planning to become pregnant within 1 year;\n7. Any terminal condition with an estimated life expectancy of \\\u003C 6 months;\n8. Current participation in other clinical trials.","ALL","18 Years",{"count":67,"type":68},112,"ESTIMATED","INTERVENTIONAL",[71],"NA","The study aims to explore the efficacy and safety of erythrocytapheresis in chronic mountain sickness",[74],"Chronic Mountain Sickness","2026-03-29",{"date":77,"type":78},"2026-04-02","ACTUAL",{"date":80,"type":78},"2025-07-21",{"date":82,"type":68},"2029-10-01",{"name":5,"class":6},1]